ES2104771T3 - Procedimiento para purificar el virus de la hepatitis a (vha), el virus de dicha forma purificado y composiciones de vacunas que los contienen. - Google Patents

Procedimiento para purificar el virus de la hepatitis a (vha), el virus de dicha forma purificado y composiciones de vacunas que los contienen.

Info

Publication number
ES2104771T3
ES2104771T3 ES92109524T ES92109524T ES2104771T3 ES 2104771 T3 ES2104771 T3 ES 2104771T3 ES 92109524 T ES92109524 T ES 92109524T ES 92109524 T ES92109524 T ES 92109524T ES 2104771 T3 ES2104771 T3 ES 2104771T3
Authority
ES
Spain
Prior art keywords
virus
hepatitis
hav
purify
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92109524T
Other languages
English (en)
Inventor
Vittoria Pellegrini
Nicoletta Fineschi
Arie J Zuckerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Biocine SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocine SpA filed Critical Biocine SpA
Application granted granted Critical
Publication of ES2104771T3 publication Critical patent/ES2104771T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE DESCRIBE UN PROCESO PARA LA PURIFICACION DEL VIRUS DE LA HEPATITIS (A) QUE PERMITE OBTENER CON BUEN RENDIMIENTO UN PRODUCTO PURO, EN EL CUAL EL MATERIAL ORGANICO RECOGIDO MEDIANTE CENTRIFUGACION DESPUES DE LA LISIS DE LAS CELULAS DEL CULTIVO SE EXPONE A UN FILTRADO POR GEL Y SUCESIVAMENTE A UNA CROMATOGRAFIA DE INTERCAMBIO DE IONES.
ES92109524T 1991-06-18 1992-06-05 Procedimiento para purificar el virus de la hepatitis a (vha), el virus de dicha forma purificado y composiciones de vacunas que los contienen. Expired - Lifetime ES2104771T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI911662A IT1248075B (it) 1991-06-18 1991-06-18 Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.

Publications (1)

Publication Number Publication Date
ES2104771T3 true ES2104771T3 (es) 1997-10-16

Family

ID=11360137

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92109524T Expired - Lifetime ES2104771T3 (es) 1991-06-18 1992-06-05 Procedimiento para purificar el virus de la hepatitis a (vha), el virus de dicha forma purificado y composiciones de vacunas que los contienen.

Country Status (8)

Country Link
US (2) US5607851A (es)
EP (1) EP0522291B1 (es)
JP (1) JPH07177882A (es)
AT (1) ATE156187T1 (es)
DE (1) DE69221225T2 (es)
DK (1) DK0522291T3 (es)
ES (1) ES2104771T3 (es)
IT (1) IT1248075B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
USRE37303E1 (en) * 1992-01-10 2001-07-31 Institut National Del La Sante Et De La Recherche Medicale Imidazole compounds and their therapeutic applications
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
FR2696748B1 (fr) * 1992-10-14 1994-12-30 Pasteur Merieux Serums Vacc Procédé de préparation d'antigènes et de vaccins de l'hépatite A (HAV).
JPH11511326A (ja) 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびａａｖの精製
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
AU732703B2 (en) * 1996-11-20 2001-04-26 Crucell Holland B.V. An improved method for the production and purification of adenoviral vectors
US6544769B1 (en) 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
WO1998026048A1 (en) * 1996-12-13 1998-06-18 Schering Corporation Methods for purifying viruses
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6855535B2 (en) * 2001-12-10 2005-02-15 Baxter Healthcare S.A. Method of large scale production of Hepatitis A virus
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CN101080488A (zh) * 2004-11-03 2007-11-28 因特罗根治疗公司 生产和纯化腺病毒载体的新方法
JP4670583B2 (ja) * 2005-10-20 2011-04-13 チッソ株式会社 水溶性カチオン性磁気微粒子を用いた脂質ベシクルの分離又は検出方法
WO2009100521A1 (en) * 2008-02-12 2009-08-20 Sanofi Pasteur Limited Methods using ion exchange and gel filtration chromatography for poxvirus purification
SG184833A1 (en) 2010-04-14 2012-11-29 Emd Millipore Corp Methods of producing high titer, high purity virus stocks and methods of use thereof
CN101816786B (zh) * 2010-04-30 2012-09-05 长春生物制品研究所有限责任公司 一种甲型肝炎灭活疫苗及其制备方法
EP3695849A1 (en) 2019-02-13 2020-08-19 Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH Method for extracting hepatitis a virus (hav) antigen from cell culture
US20230212530A1 (en) * 2020-06-16 2023-07-06 Hoya Technosurgical Corporation Virus purification method using apatite column

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
JPS6147186A (ja) * 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst インフルエンザウイルスの精製方法
JPS6147185A (ja) * 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
US4673634A (en) * 1985-03-08 1987-06-16 The United States Of America As Represented By The Department Of Health And Human Services Purified antigen from non-A, non-B hepatitis causing factor
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
EP0327801A1 (en) * 1988-01-08 1989-08-16 Deutsches Primatenzentrum Gesellschaft Mbh HIV-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions
US5004688A (en) * 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
JPH085804B2 (ja) * 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン

Also Published As

Publication number Publication date
US5719049A (en) 1998-02-17
EP0522291A1 (en) 1993-01-13
ITMI911662A0 (it) 1991-06-18
ATE156187T1 (de) 1997-08-15
DE69221225D1 (de) 1997-09-04
JPH07177882A (ja) 1995-07-18
ITMI911662A1 (it) 1992-12-18
DK0522291T3 (da) 1997-08-18
US5607851A (en) 1997-03-04
DE69221225T2 (de) 1998-03-19
IT1248075B (it) 1995-01-05
EP0522291B1 (en) 1997-07-30

Similar Documents

Publication Publication Date Title
ES2104771T3 (es) Procedimiento para purificar el virus de la hepatitis a (vha), el virus de dicha forma purificado y composiciones de vacunas que los contienen.
MX166895B (es) Procedimiento para purificar organofosfitos terciarios
ES2032802T3 (es) Sucedaneo de la sangre, semisintetico, extrapuro.
FR1284206A (fr) Procédé de purification de gaz légers à l'aide de tamis moléculaires
ES2057191T3 (es) Metodo de produccion para una composicion que contiene proteinas.
DK173883D0 (da) Substituerede 8-phenylxanthiner
ES2106784T3 (es) Factor de transferencia y metodos de uso.
ES2138603T3 (es) Procedimiento para el aislamiento de los factores ix, x y ii altamente purificados a partir del complejo protrombinico o del plasma humano.
JPS51123140A (en) Photosensitive compositions and processing method thereof
ES504199A0 (es) Un metodo para aumentar el rendimiento de vha en un cultivo celular in vitro
ES2109557T3 (es) Procedimiento para la obtencion de carbonato de etilenglicol purificado (egc).
FI844013L (fi) Foerfarande foer att polymerisera eten och sampolymerisera eten med alfa-olefiner, och katalysatorer, som anvaends i foerfarandet.
ES346460A1 (es) Un procedimiento para la preparacion de un lipopolisacaridono toxico, purificado.
FR1145934A (fr) Perfectionnements à l'éclairage des plaques transparentes par lumière frisante
ES2052063T3 (es) Motor paso a paso multipolar.
FR1278703A (fr) Perfectionnements à l'éclairage des plaques transparentes, par lumière frisaute
ES2064071T3 (es) Antigeno viral de hepatitis delta, procedimiento para su purificacion y su utilizacion.
ES2193742T3 (es) Composiciones de vacuna que contienen salmonella typhi.
MX9303771A (es) Proteina viral icp27 del virus vhs-2, proceso para su preparacion y composicion de vacuna que la incluye.
ES2030676T3 (es) Procedimiento para la preparacion de alquilaril eteres.
JPS524854A (en) Objective=lens used for microscope
IT1185760B (it) Attrattivo composito per insetti per i maschi della nottua gamma (autographa gamma)
SU840592A1 (ru) Способ удалени влаги из воздухаВ уСТАНОВКАХ КОНдициОНиРОВАНи
GT199800019A (es) Proceso para producir eters de oxima ( z ) -azabiciclo en un unico recipiente.
GT198065142A (es) Purinas sustituidas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 522291

Country of ref document: ES